Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

US Army
US Department of Justice
Johnson and Johnson
Boehringer Ingelheim
McKinsey
Harvard Business School

Generated: July 23, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,618,141

Try a free trialSee Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,618,141 protect, and when does it expire?

Patent 8,618,141 protects NEXAVAR and is included in one NDA.

This patent has fifteen patent family members in eleven countries.

Summary for Patent: 8,618,141
Title:Aryl ureas with angiogenesis inhibiting activity
Abstract: This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.
Inventor(s): Dumas; Jacques (Bethany, CT), Scott; William J. (Guilford, CT), Elting; James (Madison, CT), Hatoum-Makdad; Holia (Hamden, CT)
Assignee: Bayer Healthcare LLC (Whippany, NJ)
Application Number:13/551,884
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,618,141
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 8,618,141
Patent Claim Types:
see list of patent claims
Use; Formulation;

Drugs Protected by US Patent 8,618,141

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bayer Hlthcare NEXAVAR sorafenib tosylate TABLET;ORAL 021923-001 Dec 20, 2005 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF ADVANCED RENAL CELL CARCINOMA ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Julphar
Colorcon
Deloitte
McKesson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.